About Us

Changes in the Philippine healthcare industry merit new solutions

Drug Development

  • Diabetes and Rare Diseases
  • Immunologic Therapy for Cancer
  • HIV Vaccine, Dementia, Alzheimers

Healthcare Sector

  • Increasing healthcare spending
  • PHP 655B with 10.5% CAGR from 2016-2021
  • 8.2% of Filipinos will be above 60 by end of 2018

Clinical Trial Regulation by 2019

  • Clinical Trial Regulation by 2019
  • Mandatory Adverse Event Reporting
  • Mandatory Phase IV Trials

Who We Are

Incorporated as Pi Health Inc. and registered as a CRO with a License to Operate (LTO) by the Philippine Food and Drug Administration in 2018, PIVOT seeks to address these changes through innovative ways

  • to increase impactful medical research output of the Philippines on par with advanced countries
  • to raise the capability and visibility of Filipino Principal Investigators in international journal publications
  • to contribute to the development of life-changing medications for Filipino patients from all walks of life


These are our partners.